Pemetrexed Injection, Powder, For Solution
Product Images NDC 43547-632

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 43547-632). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A Kaplan-Meier overall survival curve showing survival percentages over time in months for two treatment arms, labeled PI+P+C (solid black line) and PI+C (dashed gray line). The y-axis shows overall survival (%) from 0 to 100%, and the x-axis shows time in months from 0 to 21. Below the graph, the number of patients at risk at various time points is listed for each treatment group.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A survival probability plot comparing Pemetrexed for injection plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC) over a 30-month period. The y-axis represents survival probability from 0 to 1, and the x-axis represents survival time in months. The chart includes numbers of patients at risk at various time points for both treatment groups.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A survival probability Kaplan-Meier curve comparing Pemetrexed for injection versus placebo over time in months. The solid line represents Pemetrexed, and the dotted line represents placebo. The chart shows survival probabilities declining from 1.0 to around 0.15 over approximately 42 months. Below the graph, a table details the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A Kaplan-Meier survival curve comparing survival probability over time in months for Pemetrexed for injection versus placebo. The solid line represents Pemetrexed, and the dotted line represents placebo. The graph includes patient numbers at risk for each group at various time points up to 36 months.*
FDA Label Image

Carton Label (Carton.png)

Carton Label (Carton.png)
Packaging label for Pemetrexed injection, USP, 100 mg per vial, single-dose vial for intravenous use only. The label includes storage instructions, preparation details, and manufacturer information, with Solco Healthcare US, LLC as the distributor. The label features a blue and white color scheme with a barcode and regulatory information.*
FDA Label Image

Container Label (Image 01)

Container Label (Image 01)
Label for Pemetrexed injection, USP 100 mg/vial, a powder for solution administered intravenously. The label shows the NDC 43547-632-01 and states it is for prescription use only. Distributed by Solco Healthcare US, LLC, the label notes storage conditions and includes a barcode and revision date of 12/2023.*
FDA Label Image

Structural Formula (Image 02)

Structural Formula (Image 02)
Chemical structure of Pemetrexed disodium hydrate, showing its molecular arrangement including multiple ring systems and sodium carboxylate groups with hydration (2.5 H2O).*
FDA Label Image

Figure 10 (Image 03)

Figure 10 (Image 03)
A survival probability curve comparing Pemetrexed disodium plus Cisplatin (PC) versus Cisplatin alone over time in months. The y-axis represents survival probability from 0.0 to 1.0, and the x-axis shows survival time up to 30 months. The chart includes patient counts at risk for each group at different time points below the x-axis.*
FDA Label Image

Figure 3 (Image 05)

Figure 3 (Image 05)
A Kaplan-Meier survival curve chart comparing survival probability over 30 months for Pemetrexed for Injection + Cisplatin (PC) versus Gemcitabine + Cisplatin (GC). The chart shows a higher survival probability trend for the PC group across the timeline. The bottom includes a table listing the number of patients at risk in each treatment group at several time points.*
FDA Label Image

Figure 4 (Image 06)

Figure 4 (Image 06)
A survival probability curve comparing two chemotherapy regimens over 30 months. The solid line represents Pemetrexed for injection plus Cisplatin (PC), and the dotted line represents Gemcitabine plus Cisplatin (GC). Below the graph, the number of patients at risk for each group is listed at various time points.*
FDA Label Image

Figure 6 (Image 08)

Figure 6 (Image 08)
A Kaplan-Meier survival curve showing survival probability over time in months for Pemetrexed for injection versus placebo. The plot includes a solid line for Pemetrexed and a dotted line for placebo, with a table below indicating the number of patients at risk at different time points for each group.*
FDA Label Image

Figure 7 (Image 09)

Figure 7 (Image 09)
A survival probability curve comparing Pemetrexed for injection and placebo over survival time in months. The solid line represents Pemetrexed for injection, while the dotted line shows placebo. Numbers of patients at risk for each group are provided below the graph at different time points from 0 to 42 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.